1. Market Research
  2. > RNL BIO Co., Ltd. - Product Pipeline Review - 2013

RNL BIO Co., Ltd. - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 22 pages

RNL BIO Co., Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “RNL BIO Co., Ltd. - Product Pipeline Review - 2013” provides data on the RNL BIO Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, RNL BIO Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from RNL BIO Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- RNL BIO Co., Ltd. - Brief RNL BIO Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of RNL BIO Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of RNL BIO Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the RNL BIO Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate RNL BIO Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of RNL BIO Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the RNL BIO Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with RNL BIO Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of RNL BIO Co., Ltd. and identify potential opportunities in those areas.

Table Of Contents

RNL BIO Co., Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
RNL BIO Co., Ltd. Snapshot 4
RNL BIO Co., Ltd. Overview 4
Key Information 4
Key Facts 4
RNL BIO Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
RNL BIO Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
RNL BIO Co., Ltd. - Pipeline Products Glance 9
RNL BIO Co., Ltd. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
RNL BIO Co., Ltd. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
RNL BIO Co., Ltd. - Drug Profiles 12
Astrostem 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Autologous Adipose Tissue Derived Mesenchymal Stem Cell 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Jointstem 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Vascostem 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
RNL BIO Co., Ltd. - Pipeline Analysis 16
RNL BIO Co., Ltd. - Pipeline Products by Therapeutic Class 16
RNL BIO Co., Ltd. - Pipeline Products by Route of Administration 18
RNL BIO Co., Ltd. - Recent Pipeline Updates 19
RNL BIO Co., Ltd. - Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22



List of Tables

RNL BIO Co., Ltd., Key Information 4
RNL BIO Co., Ltd., Key Facts 4
RNL BIO Co., Ltd. - Pipeline by Indication, 2013 6
RNL BIO Co., Ltd. - Pipeline by Stage of Development, 2013 7
RNL BIO Co., Ltd. - Monotherapy Products in Pipeline, 2013 8
RNL BIO Co., Ltd. - Phase II, 2013 9
RNL BIO Co., Ltd. - Phase I, 2013 10
RNL BIO Co., Ltd. - Preclinical, 2013 11
RNL BIO Co., Ltd. - Pipeline By Therapeutic Class, 2013 17
RNL BIO Co., Ltd. - Pipeline By Route of Administration, 2013 18
RNL BIO Co., Ltd. - Recent Pipeline Updates, 2013 19



List of Figures

RNL BIO Co., Ltd. - Pipeline by Indication, 2013 6
RNL BIO Co., Ltd. - Pipeline by Stage of Development, 2013 7
RNL BIO Co., Ltd. - Monotherapy Products in Pipeline, 2013 8
RNL BIO Co., Ltd. - Pipeline By Therapeutic Class, 2013 16
RNL BIO Co., Ltd. - Pipeline By Route of Administration, 2013 18



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.